STADA at a Glance

The business model

• Focus on products with off-patent active pharmaceutical ingredients in the health care and, in particular, in the pharmaceutical market
• Core segments in financial year 2012
  • Generics (66% of Group sales)
  • Branded Products (32% of Group sales)
• Strategic success factors
  • Orientation on long-term growth markets
  • Strong presence in European market regions and continuous expansion focused on Eastern Europe
  • Comprehensive generics portfolio and ongoing growth in attractive margin branded products
  • Functionally organized Group with short decision-making processes and strong local presence in the market regions at the same time
  • Successful product development with a “time and cheap to market” strategy and cooperations with experienced partners for complex products
  • Organic growth complemented by acquisitions with concentration on high-growth emerging markets and high-margin branded products segment
  • Efficient cost management and the program “STADA – build the future” with the aim of strengthening the mid and long-term earnings potential

Successful financial year 2012

• Group sales increase to EUR 1.84 billion (+7%) – adjusted +1%
• All reported key earnings figures exceed previous year
  • Reported net income increases to EUR 86.5 million (>100%)
  • Reported EBITDA shows an increase to EUR 323.8 million (+45%), adjusted EBITDA margin 20.0% (previous year: 19.7%)
  • Earnings per share increases to EUR 1.46 (>100%)
• Increase in many adjusted key earnings figures
  • Adjusted net income increases slightly to EUR 147.9 million (previous year: EUR 146.6 million)
  • Adjusted EBITDA shows an increase to EUR 367.5 million (previous year: EUR 337.2 million)
  • Adjusted earnings per share increases slightly to EUR 2.50 (previous year: EUR 2.49)
• Continued strong growth in emerging markets especially in Russia (+23%)
• International expansion of self-pay patient portfolio from substantial growth in branded products (+26%)
• At 717 product launches worldwide, the highest number in corporate history (previous year: 600 product launches)
• Active acquisition policy with attractive purchases – integration of acquired business activities as planned
• Stable financing structure – additional promissory note in the amount of EUR 100 million successfully secured
• Conclusion of the personnel reduction as part of “STADA – build the future” a year earlier than originally planned
• Significantly increased dividend proposal of 35.1% to EUR 0.50 per STADA common share (previous year: EUR 0.37)

Outlook

• Further growth in Group sales in 2013 and 2014
• Opportunity in 2013 and 2014 for renewed growth in adjusted EBITDA in the high single-digit percentage area
• Long-term targets for 2014¹⁾ affirmed: Group sales of approx. EUR 2.15 billion, adjusted EBITDA of approx. EUR 430 million and adjusted net income of approx. EUR 215 million.